Bachem Holding (BANB) Aandelenoverzicht
Bachem Holding AG levert, samen met haar dochterondernemingen, producten voor onderzoek, klinische ontwikkeling en commerciële toepassing aan farmaceutische en biotechnologische bedrijven wereldwijd. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 3/6 |
BANB Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CHF 249.99
FV
70.1% ondergewaardeerd intrinsieke korting62.01%
Revenue growth p.a.
170
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Bachem Holding AG Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | CHF 74.80 |
| 52 Week Hoogtepunt | CHF 83.25 |
| 52 Week Laag | CHF 48.52 |
| Bèta | 0.81 |
| 1 maand verandering | -3.30% |
| 3 maanden verandering | 5.65% |
| 1 Jaar Verandering | 8.01% |
| 3 jaar verandering | -8.11% |
| 5 jaar verandering | -37.87% |
| Verandering sinds IPO | 434.29% |
Recent nieuws en updates
Narratiefupdate • Jul 30
BANB: Future Execution At New Facility Is Expected To Sustain Fair Value
Analysts have raised their price target on Bachem Holding to CHF81.40 from CHF78.80, citing model updates that reflect slightly higher assumed revenue growth and profit margins, a modestly lower discount rate, and a small adjustment to the future P/E input. What's in the News for Bachem Holding Bachem Holding announced the next phase of its greenfield project in Sisslerfeld in Eiken, Switzerland, involving a large scale production facility with a total investment of more than CHF 500 million.
Narratiefupdate • Jul 15
BANB: Rising Margin Expectations Will Increase Execution Risk And Restrain Upside
Analysts have raised their price target for Bachem Holding from CHF 46.00 to CHF 52.00, reflecting updated views that combine a slightly different discount rate, more cautious revenue growth assumptions, a higher projected profit margin, and a modestly lower future P/E multiple. What’s in the News for Bachem Holding ImmuPharma PLC appoints Bachem AG as manufacturing partner for the active pharmaceutical ingredient in its Kapiglucagon program, marking a key Chemistry, Manufacturing and Controls milestone for that project.Analyse-artikel • Jul 04
Does Bachem Holding (VTX:BANB) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Recent updates
Narratiefupdate • Jul 30
BANB: Future Execution At New Facility Is Expected To Sustain Fair Value
Analysts have raised their price target on Bachem Holding to CHF81.40 from CHF78.80, citing model updates that reflect slightly higher assumed revenue growth and profit margins, a modestly lower discount rate, and a small adjustment to the future P/E input. What's in the News for Bachem Holding Bachem Holding announced the next phase of its greenfield project in Sisslerfeld in Eiken, Switzerland, involving a large scale production facility with a total investment of more than CHF 500 million.Narratiefupdate • Jul 15
BANB: Rising Margin Expectations Will Increase Execution Risk And Restrain Upside
Analysts have raised their price target for Bachem Holding from CHF 46.00 to CHF 52.00, reflecting updated views that combine a slightly different discount rate, more cautious revenue growth assumptions, a higher projected profit margin, and a modestly lower future P/E multiple. What’s in the News for Bachem Holding ImmuPharma PLC appoints Bachem AG as manufacturing partner for the active pharmaceutical ingredient in its Kapiglucagon program, marking a key Chemistry, Manufacturing and Controls milestone for that project.Analyse-artikel • Jul 04
Does Bachem Holding (VTX:BANB) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narratiefupdate • Jun 22
BANB: Capacity Expansion Commitments Will Heighten Execution Risk And Restrain Upside
Analysts have raised their price target on Bachem Holding by CHF 5 to reflect updated assumptions for discount rates, growth and profitability. This move is supported by recent Street research that cites a higher target from CHF 5 at Barclays as a reference point for the new CHF level.
Narratiefupdate • Jun 05
BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework
Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.Narratiefupdate • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.Narratiefupdate • May 01
BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential
Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.
Nieuw narratief • Apr 26
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.Narratiefupdate • Apr 16
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.Narratiefupdate • Apr 02
BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential
Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.Narratiefupdate • Mar 19
BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential
Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.Narratiefupdate • Mar 05
BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence
The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.Narratiefupdate • Feb 18
BANB: Future Pipeline Execution Will Drive Upside Versus Recent Cautious Views
Analysts have adjusted their fair value estimate for Bachem Holding to CHF 76.59, reflecting updated views on growth, profitability and valuation following recent price target revisions that include a CHF 32 increase from RBC Capital and a reduction to CHF 60 from Barclays. Analyst Commentary Recent research shows a split view on Bachem Holding, with some bullish analysts lifting targets and more cautious voices trimming expectations.Narratiefupdate • Feb 04
BANB: Higher Fair Value Will Rely On Execution Of Existing Order Book
Analysts have raised their fair value estimate for Bachem Holding from CHF 100.00 to CHF 110.00, citing updated assumptions around revenue growth, profit margins and future P/E multiples that are in line with recent Street target changes, including the higher price target from RBC and the revised level from Barclays. Analyst Commentary Recent research updates around Bachem Holding give you a mixed but useful read on how the Street is thinking about valuation and execution.Narratiefupdate • Jan 21
BANB: Building K Execution Risks Will Limit Future Share Upside
Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.Narratiefupdate • Jan 07
BANB: Building K Execution Risk Will Constrain Future Upside Potential
Analysts have trimmed their average price target on Bachem Holding to CHF 60 from CHF 75, citing updated assumptions for revenue growth, profit margins and future P/E multiples that reflect a more measured outlook, even as expansion projects remain in focus. Analyst Commentary Recent street research on Bachem highlights a mix of views, with some analysts seeing potential tied to expansion projects such as Building K, while others are recalibrating expectations and price targets to reflect what they view as a more balanced risk and reward profile.Narratiefupdate • Dec 14
BANB Building K Expansion Will Define Future Upside And Execution Risk
Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.Analyse-artikel • Dec 01
At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?
While Bachem Holding AG ( VTX:BANB ) might not have the largest market cap around , it received a lot of attention from...Analyse-artikel • Oct 25
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Bachem Holding AG's ( VTX:BANB ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right...Narratiefupdate • Sep 26
Building K Production Will Serve Peptide And Oligonucleotide Therapies
Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.Analyse-artikel • Sep 18
Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyse-artikel • Aug 16
Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
SWX:BANB 1 Year Share Price vs Fair Value Explore Bachem Holding's Fair Values from the Community and select yours Some...
Nieuw narratief • Mar 02
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.Rendement voor aandeelhouders
| BANB | CH Life Sciences | CH Markt | |
|---|---|---|---|
| 7D | -0.3% | 4.7% | 1.4% |
| 1Y | 8.0% | 0.7% | 17.8% |
Rendement versus industrie: BANB overtrof de Swiss Life Sciences industrie, die het afgelopen jaar een rendement 0.7 % opleverde.
Rendement versus markt: BANB presteerde slechter dan Swiss Market, dat het afgelopen jaar een rendement van 17.8 % opleverde.
Prijsvolatiliteit
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 6.2% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.9% |
| 10% least volatile stocks in CH Market | 2.2% |
Stabiele aandelenkoers: De aandelenkoers van BANB is de afgelopen 3 maanden volatiel geweest in vergelijking met de Swiss markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van BANB is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Swiss.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1971 | 2,363 | Anne-Kathrin Stoller | www.bachem.com |
Bachem Holding AG levert, samen met haar dochterondernemingen, producten voor onderzoek, klinische ontwikkeling en commerciële toepassingen aan farmaceutische en biotechnologische bedrijven wereldwijd. Het houdt zich bezig met de ontwikkeling, productie en wettelijke ondersteuning van peptide actieve farmaceutische ingrediënten, zoals peptide en oligonucleotide nieuwe chemische entiteiten (NCE's). Het bedrijf biedt ook commerciële NCE's en generieke geneesmiddelen; en projectmanagement, kwaliteit en regelgeving, analytische, goede productiepraktijken productie, onderzoekskwaliteit productie, en levering en verticale integratie diensten.
Bachem Holding AG Samenvatting
| BANB fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | CHF 5.77b |
| Inkomsten(TTM) | CHF 148.96m |
| Inkomsten(TTM) | CHF 708.53m |
37.6x
Koers/Winstverhouding7.9x
P/S-verhoudingIs BANB overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| BANB resultatenrekening (TTM) | |
|---|---|
| Inkomsten | CHF 708.53m |
| Kosten van inkomsten | CHF 517.20m |
| Brutowinst | CHF 191.33m |
| Overige uitgaven | CHF 42.37m |
| Inkomsten | CHF 148.96m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
Mar 04, 2027
| Winst per aandeel (EPS) | 1.99 |
| Brutomarge | 27.00% |
| Nettowinstmarge | 21.02% |
| Schuld/Eigen Vermogen Verhouding | 14.4% |
Hoe presteerde BANB op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
1.2%
Huidig dividendrendement45%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/31 21:29 |
| Aandelenkoers aan het einde van de dag | 2026/07/31 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Bachem Holding AG wordt gevolgd door 17 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |
| Patrick Laager | Berenberg |